Results 1 to 10 of about 210,319 (126)
The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas [PDF]
Frontiers in Endocrinology, 2019 Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size.
Chiyuan Ma, Jin Yang, Chao Tang
exaly +7 more sources
Dopamine Agonists and Pathologic Behaviors [PDF]
Parkinson's Disease, 2012 The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson’s disease has been complicated by the emergence of pathologic behavioral patterns such as ...
Brendan J. Kelley +2 more
doaj +3 more sources
Dopamine Agonists for Pituitary Adenomas [PDF]
Frontiers in Endocrinology, 2018 Dopamine agonists (DA) are well established as first-line therapy for prolactinomas. These tumors express high levels of dopamine 2 receptors (D2R), leading to the strong efficacy of DA in reducing tumor size and hormonal secretion. Other pituitary tumor
Odelia Cooper, Yona Greenman
doaj +3 more sources
Pharmaceuticals, 2023 We reviewed gastric ulcer healing by dopamine considering several distinctive duodenal key points. Selye and Szabo describe the cysteamine-induced duodenal ulcer in rats as a duodenal stress ulcer in patients.
Predrag Sikiric +24 more
doaj +1 more source
Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease
Clinical Parkinsonism & Related Disorders, 2021 Introduction: Up to 40% of Parkinson’s disease patients taking dopamine agonist medication develop impulse control behaviors which can have severe negative consequences.
Alison Hall +5 more
doaj +1 more source
Observations on sleep-disordered breathing in idiopathic Parkinson's disease. [PDF]
PLoS ONE, 2014 BACKGROUND: This study has two main goals: 1.) to determine the potential influence of dopaminergic drugs on sleep-disordered breathing (SDB) in Parkinson's disease (PD) and 2.) to elucidate whether NREM and REM sleep differentially impact SDB severity ...
Philipp O Valko +4 more
doaj +1 more source
Clinical Parkinsonism & Related Disorders, 2023 Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson’s disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and affinity, chemical composition, receptor ...
Stuart H. Isaacson +4 more
doaj +1 more source
Alʹmanah Kliničeskoj Mediciny, 2023 The priority treatment approach for prolactinomas is therapy with dopamine agonists, which allows for elimination of clinical symptoms, normalization of prolactin levels, reduction of the adenoma size and prevention of metabolic abnormalities in the ...
Irena A. Ilovayskaya, Gulnar R. Vagapova
doaj +1 more source
Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors
Parkinson's Disease, 2021 Objective. To investigate the use of dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors in the Norwegian population, between 1 July 2006 and 31 December 2016.
Caroline D. Binde +2 more
doaj +1 more source
Dopamine agonists and antipsychotics [PDF]
European Journal of Endocrinology, 2020 There can potentially be a number of clinical interactions that could adversely affect patient outcomes in a patient with a prolactinoma and psychiatric disease that might require antipsychotic and dopamine agonist treatment. Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size
openaire +2 more sources